CN Patent

CN101076343A — A2a腺苷受体激动剂的应用

Assigned to Gilead Palo Alto Inc · Expires 2007-11-21 · 18y expired

What this patent protects

通过将一种包含regadenoson(一种腺苷A 2A 受体激动剂)的药物组合物的多个剂量给予进行心肌显像的人而实现的心肌显像方法，其中药物组合物以足以在平均冠脉峰值流速方面获得至少最小增加的量给予。

USPTO Abstract

通过将一种包含regadenoson(一种腺苷A 2A 受体激动剂)的药物组合物的多个剂量给予进行心肌显像的人而实现的心肌显像方法，其中药物组合物以足以在平均冠脉峰值流速方面获得至少最小增加的量给予。

Drugs covered by this patent

Patent Metadata

Patent number
CN101076343A
Jurisdiction
CN
Classification
—
Expires
2007-11-21
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Palo Alto Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.